Drugs / DSTA4637S
DSTA4637S
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03162250 | Jul 2017 → Jan 2020 | bacterial infectious disease | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02596399 | Nov 2015 → May 2016 | — | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSTA4637S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02596399 ↗ |
| Known as | Anti-s. aureus tac | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297941 ↗ |
| Known as | RG-7861 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297941 ↗ |
| Route | Intravenous | “Participants will receive DSTA4637S intravenously on Day 1.” NCT02596399 ↗ |